Hodges Capital Management Inc. Gilead Sciences, Inc. Transaction History

Hodges Capital Management Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 08, 2019	SELL	$60.54 - $79.0 $285,748 - $372,880	-4,720 Closed	0 $0
Q3 2018 Oct 29, 2018	SELL	$71.28 - $78.92 $1,782 - $1,973	-25 Reduced 0.53%	4,720 $364,000
Q2 2018 Jul 26, 2018	SELL	$64.88 - $75.68 $659,180 - $768,908	-10,160 Reduced 68.17%	4,745 $336,000
Q1 2018 May 03, 2018	SELL	$72.84 - $88.8 $140,435 - $171,206	-1,928 Reduced 11.45%	14,905 $1.12 Million
Q4 2017 Feb 06, 2018	SELL	$71.15 - $83.52 $1.69 Million - $1.99 Million	-23,806 Reduced 58.58%	16,833 $1.21 Million
Q3 2017 Nov 02, 2017	BUY	$72.11 - $85.47 $2.93 Million - $3.47 Million	40,639	40,639 $3.29 Million

1,930

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Hodges Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hodges Capital Management Inc. with notifications on news.